EP11.03. Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Tianqing Chu
Meta Tag
Speaker Tianqing Chu
Topic Metastatic NSCLC: Immunotherapy - Retrospective
treatment methods
advanced NSCLC
EGFR/HER2 exon 20 insertion mutations
anti-angiogenic therapy
progression-free survival
overall survival
bevacizumab chemotherapy
targeted therapy
Powered By